Amedisys, Inc. (NASDAQ:AMED) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Amedisys, Inc. (NASDAQ:AMED) have been assigned a consensus recommendation of “Hold” from the six brokerages that are covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $100.75.

Separately, Stephens restated an “equal weight” rating and set a $101.00 price target on shares of Amedisys in a report on Tuesday, March 4th.

Institutional Investors Weigh In On Amedisys

Several large investors have recently made changes to their positions in the company. Blue Trust Inc. lifted its stake in Amedisys by 55.1% in the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after acquiring an additional 124 shares during the last quarter. HBW Advisory Services LLC acquired a new stake in shares of Amedisys in the 4th quarter valued at $38,000. Versant Capital Management Inc boosted its holdings in Amedisys by 68.5% in the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after purchasing an additional 183 shares in the last quarter. Johnson Financial Group Inc. acquired a new position in Amedisys during the fourth quarter worth $55,000. Finally, KBC Group NV bought a new position in Amedisys during the third quarter valued at about $63,000. Institutional investors own 94.36% of the company’s stock.

Amedisys Price Performance

Shares of NASDAQ:AMED opened at $92.37 on Friday. The company’s fifty day moving average is $92.00 and its two-hundred day moving average is $92.97. The company has a market cap of $3.03 billion, a P/E ratio of 36.65, a price-to-earnings-growth ratio of 1.78 and a beta of 0.76. Amedisys has a 12-month low of $82.15 and a 12-month high of $98.95. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. Equities analysts expect that Amedisys will post 4.4 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.